Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst

Benzinga_recent_news04-18 02:06

The company, formerly MindMed, is focused on developing psychedelic-based therapies for psychiatric and neurological disorders. On Thursday, the U.S government is reportedly preparing to take a closer...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628869017?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/17/Mental-Health-Care-Therapy-Concept--Psyc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-18 02:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628869017","market":"sh","top_or_hot":-1,"title":"Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst","media":"Benzinga_recent_news","content":"<div>\n<p>The company, formerly MindMed, is focused on developing psychedelic-based therapies for psychiatric and neurological disorders.\nOn Thursday, the U.S government is reportedly preparing to take a closer...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51894510/definium-therapeutics-anxiety-drug-a-multi-billion-opportunity-analyst\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDefinium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-18 02:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51894510/definium-therapeutics-anxiety-drug-a-multi-billion-opportunity-analyst><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The company, formerly MindMed, is focused on developing psychedelic-based therapies for psychiatric and neurological disorders.\nOn Thursday, the U.S government is reportedly preparing to take a closer...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51894510/definium-therapeutics-anxiety-drug-a-multi-billion-opportunity-analyst\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51894510/definium-therapeutics-anxiety-drug-a-multi-billion-opportunity-analyst","article_id":"2628869017","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/17/Mental-Health-Care-Therapy-Concept--Psyc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/04/51894510/definium-therapeutics-anxiety-drug-a-multi-billion-opportunity-analyst","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628869017","pubTimestamp":1776449160,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Stifel starts Definium coverage, citing strong DT120 potential in anxiety and key 2026 trial catalysts shaping outlook.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","DFTX":"Definium Therapeutics"},"translate_title":"Definium Therapeutics焦虑药物数十亿美元的机会：分析师","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1.5},"content_text":"The company, formerly MindMed, is focused on developing psychedelic-based therapies for psychiatric and neurological disorders.\nOn Thursday, the U.S government is reportedly preparing to take a closer look at ibogaine, a psychedelic substance used abroad for conditions such as post-traumatic stress disorder (PTSD), as part of a broader effort to evaluate its safety and potential medical value.\nDT120, previously known as MM120, is an orally disintegrating tablet formulation of lysergide D-tartrate (LSD) designed with fast-dissolve technology.\nStifel's investment thesis rests heavily on DT120's probability of success in GAD, with data anticipated in the early third quarter of 2026.\nThe analyst described GAD as a major \"white space\" within neuropsychiatry, where even modest market penetration could translate into a multi-billion-dollar opportunity.\nWhile the outlook for MDD is viewed as somewhat riskier, Matteis noted that DT120 still has a credible chance of success, with data expected in the late second quarter of 2026.\nStifel pointed to encouraging Phase 2b data and additional investigator-sponsored studies supporting DT120's efficacy in anxiety.\nDespite LSD's historical association as an illicit substance, emerging clinical evidence suggests therapeutic potential.\nOn safety, the analyst acknowledged LSD's reputation as less \"clean\" compared to other psychedelics like psilocybin, but added that DT120's current safety profile appears relatively benign.\nKey opinion leaders have largely expressed limited concern based on available data.\nAnalyst Matteis initiated with a Buy rating and price forecast of $30.\nStifel also argued that the broader psychedelics space remains undervalued, even as Definium holds one of the largest market capitalizations among peers.\nThe firm expects multiple companies in the sector to succeed, with Definium positioned as a leading contender.\nThe company reported $411.6 million in cash, cash equivalents, and investments as of December 31, 2025, expected to fund operations into 2028.\nDFTX Price Action: Definium Therapeutics shares were up 0.89% at $22.86 at the time of publication on Friday. The stock is approaching its 52-week high of $23.41, according to Benzinga Pro data.\nimage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628869017","isCrawlerRequest":true}